Phenotype
|
Fish
|
Conditions
|
Figures
|
visceral fat wnt10b expression decreased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat acadl expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
whole organism decreased length, abnormal
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: unsaturated fatty acid, chemical treatment by diet: oleic acid, chemical treatment by diet: palmitoleic acid
|
Fig. 3
from Zhang et al., 2022
|
whole organism length, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 3
from Zhang et al., 2022
|
trunk increased circumference, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 2 ,
Fig. 3
from Zhang et al., 2022
|
visceral fat phyh expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
whole organism increased weight, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 2 ,
Fig. 3
from Zhang et al., 2022
|
visceral fat cebpa expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat increased volume, abnormal
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: saturated fatty acid, chemical treatment by diet: Stearic acid(d3), chemical treatment by diet: Palmitic acid(d3)
|
Fig. 3
from Zhang et al., 2022
|
visceral fat pck1 expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat acadl expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat lpin1a expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat cebpa expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat cebpd expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat pparaa expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat pparab expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat increased volume, abnormal
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: unsaturated fatty acid, chemical treatment by diet: oleic acid, chemical treatment by diet: palmitoleic acid
|
Fig. 3
from Zhang et al., 2022
|
visceral fat pck1 expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat cebpb expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat phyh expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat fasn expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
whole organism increased weight, abnormal
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: unsaturated fatty acid, chemical treatment by diet: oleic acid, chemical treatment by diet: palmitoleic acid
|
Fig. 3
from Zhang et al., 2022
|
visceral fat acox1 expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat wnt10b expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat cebpb expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
whole organism decreased length, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 2 ,
Fig. 3
from Zhang et al., 2022
|
trunk increased circumference, abnormal
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: unsaturated fatty acid, chemical treatment by diet: oleic acid, chemical treatment by diet: palmitoleic acid
|
Fig. 3
from Zhang et al., 2022
|
visceral fat cebpd expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat pparab expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat fasn expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat acaa1 expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat sfrp5 expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat pparg expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
whole organism weight, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 3
from Zhang et al., 2022
|
vertebral column decreased length, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 2
from Zhang et al., 2022
|
visceral fat acaca expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat increased volume, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 2 ,
Fig. 3
from Zhang et al., 2022
|
visceral fat acaa1 expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat pparg expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat lpin1a expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
trunk increased circumference, abnormal
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: saturated fatty acid, chemical treatment by diet: Stearic acid(d3), chemical treatment by diet: Palmitic acid(d3)
|
Fig. 3
from Zhang et al., 2022
|
visceral fat sfrp5 expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
visceral fat pparaa expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
whole organism decreased length, abnormal
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: saturated fatty acid, chemical treatment by diet: Stearic acid(d3), chemical treatment by diet: Palmitic acid(d3)
|
Fig. 3
from Zhang et al., 2022
|
visceral fat acaca expression increased amount, abnormal
|
scdzf3016/zf3016 (AB)
|
standard conditions
|
Fig. 6
from Zhang et al., 2022
|
visceral fat volume, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 3
from Zhang et al., 2022
|
visceral fat acox1 expression amount, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 6
from Zhang et al., 2022
|
trunk circumference, ameliorated
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: polyunsaturated fatty acid, chemical treatment by diet: EPA (d5), chemical treatment by diet: docosahexaenoic acid
|
Fig. 3
from Zhang et al., 2022
|
whole organism increased weight, abnormal
|
scdzf3016/zf3016 (AB)
|
chemical treatment by diet: saturated fatty acid, chemical treatment by diet: Stearic acid(d3), chemical treatment by diet: Palmitic acid(d3)
|
Fig. 3
from Zhang et al., 2022
|
liver increased size, ameliorated
|
scdzf3016/+; gz32Tg; zf3013Tg; zf3014Tg
|
chemical treatment by environment: doxycycline
|
Fig. 5
from Yao et al., 2018
|
liver increased size, ameliorated
|
scdzf3016/+; gz26Tg; gz32Tg; zf3013Tg
|
chemical treatment by environment: doxycycline
|
Fig. 5
from Yao et al., 2018
|